Shikonin can bind to the structural domain of the PAK1 kinase binding pocket, and Shikonin inhibits the activation of PAK1 and its downstream signaling pathway proteins to reduce the proliferation of pancreatic cancer cells and induce apoptosis, thus achieving a good therapeutic effect on pancreatic cancer [38]. This evidence concerns the gene PAK1 and familial pancreatic carcinoma.